| 1. |
Jarius S, Wildemann B. The history of neuromyelitisoptica[J]. J Neuroinflammation, 2013, 10: 8. DOI: 10.1186/1742-2094-10-8.
|
| 2. |
Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positiveNMO spectrum disorders[J]. Neurology, 2014, 82(5): 474-481.
|
| 3. |
Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitisoptica and relateddisorders[J]. J Neuroinflammation, 2011, 8: 184. DOI: 10.1186/1742-2094-8-184.
|
| 4. |
Kitley J, Waters P, Woodhall M, et al. Neuromyelitisoptica spectrum disorderswith aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study[J]. JAMA Neurol, 2014, 71(3): 276-283. DOI: 10.1001/jamaneurol.2013.5857.
|
| 5. |
van Pelt ED, Wong YY, Ketelslegers IA, et al. Neuromyelitisoptica spectrum disorders: comparison of clinical andmagnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgGseropositive cases in the Netherlands[J]. Eur J Neurol, 2016, 23(3): 580-587. DOI: 10.1111/ene.12898.
|
| 6. |
Pröbstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype[J]. J Neuroinflammation, 2015, 12: 46. DOI: 10.1186/s12974-015-0256-1.
|
| 7. |
Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: amulticenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-termoutcome[J]. J Neuroinflammation, 2016, 13(1): 280. DOI: 10.1186/s12974-016-0719-z.
|
| 8. |
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. DOI: 10.1212/wnl.0000000000001729.
|
| 9. |
Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica[J]. Neurology, 2006, 66(10): 1485-1489. DOI: 10.1212/01.wnl.0000216139.44259.74.
|
| 10. |
Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients[J]. Neurology, 2002, 59(8): 1224-1231. DOI: 10.1212/WNL.59.8.1224.
|
| 11. |
Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases[J]. Mult Scler, 2016, 22(14): 1821-1829. DOI: 10.1177/1352458516631038.
|
